Medicines
Update of 01/09/2025
EDUCTYL® adults
potassium acid tartrate, sodium bicarbonate
Forms and presentations
Effervescent suppository: Boxes of 6 and 12, under thermoformed blister packs.Composition
| suppository | |
| Potassium acid tartrate
|
1,15 g |
| Sodium bicarbonate
|
0,70 g |
Excipient with known effect: each suppository contains 0,210 g of soya lecithin.
Indications
- Symptomatic treatment of constipation, in particular in cases of rectal dyschezia.
- Preparation for endoscopic examinations of the rectum.
Dosage and administration
DosageAdults: one suppository a few minutes before the chosen time for defecation.
Method of administration:
Rectal route.
Contraindications
- Hypersensitivity to the active substances or to any of the excipients listed in the Composition section.
- Hypersensitivity to peanut or soya, due to the presence of soya lecithin.
- Abdominal pain syndrome of undetermined and inflammatory cause (ulcerative proctocolitis, Crohn's disease...).
Warnings and precautions
Warnings:
Prolonged use should be discouraged.
Drug treatment of constipation is only an adjunct to dietary and hygiene treatment:- enrichment of the diet with vegetable fibres and drinks;
- Advice on physical activity and rehabilitation of evacuation.
It is preferable not to use Éductyl in cases of hemorrhoidal flare-ups, anal fissures, or hemorrhagic rectocolitis.
Interactions
The data available to date do not suggest the existence of clinically significant interactions.
Fertility, pregnancy and breastfeeding
Given the available data, use in pregnant or breast-feeding women is possible occasionally.
Adverse effects
Prolonged use may give rise to sensations of anal burning and, exceptionally, to congestive proctitis.
Reporting of suspected adverse reactions:Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continuous monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals should report any suspected adverse reaction via the national reporting system: National Agency for the Safety of Medicines and Health Products (ANSM) and the network of Regional Pharmacovigilance Centres. Website: https://signalement.social-sante.gouv.fr.
Overdose
No cases of overdose have been reported.
However, prolonged use risks causing anal burning and congestive proctitis (see Undesirable effects).
Pharmacodynamics
Pharmacotherapeutic class: Other laxatives; ATC code: A06AX02.
The active ingredients release approximately 100 ml of carbon dioxide gas in the rectum in a moist environment.
The volume of carbon dioxide gas released increases intrarectal pressure on sensitive mucous membranes and thus reproduces the triggering mechanism of the defecation reflex.
Storage conditions
- Shelf life
- 2 years.
Store at a temperature not exceeding 30 °C.
Store in the original packaging, protected from moisture.
HANDLING/DISPOSAL INSTRUCTIONS
No special requirements.
Prescription, supply and reimbursement
| Marketing authorisation (AMM) | 3400930319390 (2025) suppositories per pack/6. |
| 3400930348444 (1951/91, RCP revised 19.05.2025) suppositories per pack/12. |
| Price: | 1,62 euros (Pack/12). |
| Suppository pack/6: Not reimbursed by Social Security. | |
| Suppository pack/12: Reimbursed by Social Security at 30%. Collectivities. | |
TECHNI-PHARMA Laboratories
7, rue de l'Industrie. BP 717. 98014 Monaco cdx
Tel: 00 377 92 05 75 10
Source: VIDAL · Updated on 10/11/2026. This information does not replace advice from a healthcare professional.